Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
|Videos|October 6, 2020
Applying CBT to Psychiatry
Author(s)Judith S. Beck, PhD
Judith Beck, PhD, talks Cognitive Behavior Therapy, clinical tips, and the work of her father, Dr Aaron Beck.
Advertisement
Dr Beck is President of the Beck Institute for Cognitive Behavior Therapy in Philadelphia and is a Clinical Professor of Psychology and Psychiatry at the University of Pennsylvania.
Learn more about the Beck Institute
Advertisement
Related to this article
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed.
An endocrinologist warns psychiatrists against overreading peripheral thyroid hormones and flags kelp and T3 microdosing as underrecognized risks.
Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
Adjustment disorder often goes undiagnosed after major life stressors, especially in cancer care; learn updated criteria, risks, and emerging therapies like psilocybin.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Advertisement
Advertisement
Trending on Psychiatric Times
1
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
2
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
3
Can Durable Response to Psilocybin Reshape Treatment-Resistant Depression Care?
4
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
5